Authors
Latest:
The Benefits of Enhancing Adverse Event Intake With Case Collection SystemsAutomated risk management and improved regulatory compliance among opportunities offered by case collection.
Latest:
Anchoring HEOR Evidence Generation in the Challenge from the MarketHEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.
Latest:
COVID and AMR: Crisis Reframes Antibiotics FightThe redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.
Latest:
Solving One of the Hardest Questions in Cancer: How Do We Ensure Patient Access to Medicines?Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.
Latest:
Learning and Development Is the Key to Compliance in Life SciencesEmployees must be able to retain information and remain engaged to keep pace with highly regulated industry.
Latest:
The JAKs Journey Offers Valuable Lessons for InnovatorsOpportunity remains despite regulatory and access obstacles.
Latest:
Startup Launch Guide: Avoiding 10 Common Pain PointsWith opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Latest:
Why Pharma Must Invest in Key Account Management CapabilitiesThe emergence of organized customers demands investment in advanced solutions and next-generation key account management.
Latest:
The New Era of Purpose-Led Leadership in PharmaAcross all pharma companies' activities, the COVID-19 crisis has reinforced the need for pharma leaders to commit to, communicate, and exemplify the purpose that is at the center of their strategies and organizations.
Latest:
Market Data Analytics Buyer's GuideMarket Data Analytics Buyer's Guide - Are you considering a medical claims data solution for healthcare business planning and strategy? Here’s how to make sense of the options.
Latest:
Reimbursement Benchmark Share: An Objective Measure of the Impact of Product Reimbursement on Sales PerformanceKnowing that product reimbursement affects performance and varies by geography, this article proposes the use of Reimbursement Benchmark Share (RBS) to quantify the influence of reimbursement on a product’s performance.
Latest:
A Pricing Revolution: The State OffensiveThe second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Latest:
A Roadmap to Pharma ResilienceTo safeguard patient access to life-saving medications, pharma companies must prioritize building robust resilience strategies that encompass IT systems, inventory management, risk mitigation, and regulatory compliance.
Latest:
Reaching the Healthcare Professional After COVID-19Join Pharmaceutical Executive® for an information-packed virtual conference that provides valuable advice to bolster and transform the way you reach HCPs in this time of evolution. Live: Thursday, Aug. 13, 2020 at 8:15AM EDT. On demand available after airing until Aug. 13, 2021.
Latest:
The Evolution of Healthcare Communication: Bridging the HCP-Patient DivideKey trends in healthcare communication to build trust between healthcare providers and their patients.
Latest:
The data you’re missingLatest:
The Personalized Patient Journey: A New Standard of Patient CentricityWebinar Date/Time: Wed, Apr 12, 2023 1:00 PM EDT
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
Navigating the CBD Research Landscape: Unveiling Best Practices in the Post-MMCREA EraAlthough research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
Latest:
Making the Most of the Rising Biopharma M&AsBiopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
Latest:
FDA Offers GDUFA III InsightThe Generic Drug User Fee Amendments, designed to facilitate the delivery of safe and effective generic drugs to the public and improve the predictability of the ANDA assessment process, has undergone changes that will impact the pre-ANDA and ANDA approval process—and ultimately the path for generic drugs to approval.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Gene Therapy on the Verge of Taking its Next Evolutionary StepThe shift from (ultra) rare to prevalent diseases calls for new vector manufacturing technologies
Latest:
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A RaceBig pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
Latest:
Pre-Launch Prep for Emerging Biopharmas: Data First, Then the RestMaking early commercial data and analytics decisions for launch cen future-proof their data management.
